StockNow
Calendar
Log in
Other

FDA approves AstraZeneca’s (AZN LN) Imfinzi plus Pfizer (PFE) and Astellas’ (4503 JT) Padcev for muscle-invasive bladder cancer six weeks ahead of schedule

ORIGINAL · NewsquawkFDA approves AstraZeneca’s (AZN LN) Imfinzi plus Pfizer (PFE) and Astellas’ (4503 JT) Padcev for muscle-invasive bladder cancer six weeks ahead of schedule
StockNow breaking-news AI analysis

The FDA approved the Imfinzi and Padcev combination for muscle-invasive bladder cancer six weeks ahead of schedule.

2 stocks
AZNAstraZeneca PLC$184.90Current pricePFEPfizer Inc.$28.84Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
U.S. Economy

US PPI (Oct MM) 0.3% vs. Exp. 0.4% (Prev. 1.4%)

U.S. Economy

US PPI PCE Components (Oct)

U.S. Markets

Nvidia’s (NVDA) board approached Arm (ARM) CEO Rene Haas as a potential successor to Jensen Huang, reports FT citing sources

NVDAARM